Kedrion was presented with an Industry Innovation Award from the US National Organization for Rare Disorders (NORD).
The award recognizes Kedrion’s therapy, RYPLAZIM®, the first FDA-approved treatment for Plasminogen Deficiency Type 1 (PLGD-1). The product was developed by our recently acquired subsidiary Prometic in Laval, Canada.
The award was presented Sunday at NORD’s Rare Impact Awards at the Rock & Roll Hall of Fame in Cleveland, Ohio. NORD holds these Awards annually to recognize individuals and organizations making extraordinary strides on behalf of the millions of Americans impacted by rare diseases.
Giorgio Masetti, VP, US Regional Commercial Director of Kedrion Biopharma accepted the award. “We thank NORD for this honor and for all the important work they do to support those who suffer from rare diseases and conditions. I’d also like to give special recognition to our colleagues at Prometic in Laval, Canada, whose creativity, hard work, and persistence resulted in this treatment”.
Masetti said “Our mission at Kedrion is to provide patients with rare disease and conditions relief and hope. Those suffering from Congenital Plasminogen Deficiency have suffered for years without either. We are very pleased to provide this treatment to them.”
The award was presented by Dr. Rebecca Bialas, the mother of a child with PLGD-1.“I’m so thankful that folks at Kedrion have taken up this cause and are doing all the wonderful things that they’re doing. I can’t put into words how thankful I am that this is happening,” said Rebecca. This treatment has given us hope that we can move forward with a future for our children and other patients with this disorder.” Bialas and her husband Ryan founded the Plasminogen Deficiency Foundation, whose mission is to advance the care and treatment of patients with plasminogen deficiency.
This award is a recognition of just one step in Kedrion Biopharma’s historical journey. Kedrion Executive Chairman Paolo Marcucci notes, “From our inception, we have been dedicated to the mission of providing relief to people suffering from rare and debilitating diseases and conditions. Our generous donors offer us the profound opportunity to develop life-changing therapies. In this way we see ourselves as offering a bridge between donors and patients, despair and hope. We embarked on the specific quest to develop a treatment for Congenital Plasminogen Deficiency some fifteen years ago; today we accept this award with great pride”.